We manufacture clinical-grade pluripotent stem cells

The potential of cell therapies for hard-to-treat conditions has been limited by the complex and costly logistics of autologous treatments. Therapy cells are produced “from the patient, for the patient.”

Off-the-shelf, allogenic approaches – where treatments are manufactured from a healthy donor’s cells and used for multiple patients – have moved into the spotlight as a way to accelerate time-to-patient and reduce cost significantly. Boosting immune compatibility of donor cells and ensuring their fit for therapeutic purposes is critical to realize such advanced therapy medicinal products.

This is where RHEINCELL excels.

We produce GMP-grade human induced pluripotent stem cells (iPSCs) from a unique source of clinically-approved, donor-consented umbilical cord blood units. Furthermore, we expedite allogenic approaches with a collection of HLA-homozygous iPSCs that reduce transplant rejection. Partnering with innovative developers of off-the-shelf iPSC-based therapies, we advance cell therapies where they begin: at the cell.

Have a look at
what we do
at RHEIN
CELL

NEWS

The latest news from RHEINCELL

Event

RHEINCELL IS AT ADVANCED THERAPIES 2021 VIRTUAL

Continuously seeking new partnerships and innovative collaborations, Thomas Marx is attending this year's virtual session of Advanced Therapies Congress & Expo. Cutting-edge talks and insightful discussions packed into 3 high-power days will keep Thomas busy. Make sure to join him.

19.05.2021

Read more

Event

RHEINCELL WILL BE AT ISSCR 2021 VIRTUAL

Our colleagues Thomas Marx and Dr. Katja Aschermann will be attending this year's virtual ISSCR meeting. As always, the program is an outstanding list of thought leaders, innovation drivers, and world-class researchers. We hope to see you there.

23.04.2021

Read more

News

RheinCell teams up with RegMedNet to shine a spotlight on iPSCs

RegMedNet has just announced a new In Focus feature taking a close look at how induced pluripotent stem cells can catalyze the advancement of novel cell therapies. Prepared in collaboration with RheinCell experts, the feature explores biological, clinical and commercial characteristics of iPSCs as ideal starting materials.

09.04.2021

Read more


Cookies

This website uses cookies to provide the best possible functionality.

necessary
Statistic (Google Analytics)
Google Maps